<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02369536</url>
  </required_header>
  <id_info>
    <org_study_id>Neuromed-Nutrafast-PON2015</org_study_id>
    <nct_id>NCT02369536</nct_id>
  </id_info>
  <brief_title>Efficacy of a Natural Components Mixture in the Treatment of Non Alcoholic Fatty Liver Disease (NAFLD)</brief_title>
  <acronym>NUTRAFAST</acronym>
  <official_title>Clinical Trial on the Efficacy of a Natural Components Mixture in the Treatment of Non Alcoholic Fatty Liver Disease (NAFLD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Neuromed IRCCS</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Neuromed IRCCS</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to provide clinical data to support the effectiveness of a&#xD;
      mixture of ingredients of natural origin, suitably selected and packaged, in the protection&#xD;
      from liver damage, in subjects with NAFLD.&#xD;
&#xD;
      Study design: double-blind, randomized, multicentre trial, placebo-controlled on two parallel&#xD;
      groups.&#xD;
&#xD;
      The study participants are healthy volunteers, since they do not have nor had any&#xD;
      liver-related clinical symptom, but simply laboratory (plasma levels greater than normal for&#xD;
      at least one of the liver parameters -aspartate aminotransferase AST, alanine&#xD;
      aminotransferase ALT or γ -glutamyltranspeptidase γ-GT) or instrumental (ultrasonographic&#xD;
      abnormalities of steatosic liver) tests altered as compared to normal ranges.&#xD;
&#xD;
      Three months treatment with the nutraceutical mixture or placebo. Outcomes tested before and&#xD;
      at the end of treatment - 3 months).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A correct hepatic function is highly relevant from the epidemiological point of view. In&#xD;
      Italy, Non Alcoholic Fatty Liver Disease - NAFLD - has a prevalence of 20-25% in the adult&#xD;
      population, with peaks of 50-70% within obese and type-2 diabetes populations: it is the most&#xD;
      frequent cause of hematic changes in cytonecrosis enzymes, and can explain about 90% of&#xD;
      asymptomatic high levels of transaminases. NAFLD natural history is associated with an&#xD;
      increase of cerebro and cardiovascular risk, in both healthy subjects and diabetic patients.&#xD;
&#xD;
      Its prevention and treatment are of great interest, in particular dietary and nutraceutical&#xD;
      interventions are the object of innovative research. It is also known that about 65% of&#xD;
      subjects with hepatic dysfunction consume plant extracts, like silymarin from Cardo marianum.&#xD;
      A recent trial showed an improvement of the hepatic function in subjects with NAFLD treated&#xD;
      with silybin, combined with phosphatidylcholine and vitamin E. These findings provide&#xD;
      valuable information on new therapeutic strategies, but warrant further investigation. For no&#xD;
      natural substance a health claim related to liver function was in fact approved by the&#xD;
      European Food Safety Authority (EFSA). The only exception is constituted by the food sources&#xD;
      of choline, for which the maintenance of normal hepatic function has been claimed.&#xD;
&#xD;
      The objective of this study is to provide clinical data to support the effectiveness of a&#xD;
      mixture of ingredients of natural origin, suitably selected and packaged, in the protection&#xD;
      from liver damage, in subjects with NAFLD.&#xD;
&#xD;
      Treatment: subjects will be randomized to receive the nutraceutical formulation or placebo&#xD;
      for three months, in the amount of two capsules (about 800 mg each) a day, at one time.&#xD;
&#xD;
      All subjects, after signing a written informed consent to participation in the study, will&#xD;
      receive appropriate recomendations about diet and physical exercise.&#xD;
&#xD;
      A clinic visit, with collection of the patient clinical and pharmacological history and&#xD;
      recording of any adverse event, liver ultrasound, measurement of weight and height and&#xD;
      calculation of BMI, measure of arterial blood pressure, collection of a sample of venous&#xD;
      blood, under fasting conditions, for hematochemical tests, will be made at the baseline (T0);&#xD;
      all examinations and tests (except liver ultrasound) will be repeated after three months of&#xD;
      treatment (T1).&#xD;
&#xD;
      Primary end-points of the study: hematic levels of hepatic enzymes: ALT, AST and γ-GT.&#xD;
&#xD;
      Secondary end-points of the study:&#xD;
&#xD;
        1. Hepatic function: direct and indirect bilirubin;&#xD;
&#xD;
        2. Inflammation markers: C Reactive Protein (CRP), interleukin (IL)-6, IL-1β, IL-8, IL-10,&#xD;
           Receptor for Advanced Glycation End Products (RAGE), Advanced Glycation End Products&#xD;
           (AGE), insulin-like growth factor-1 (IGF-1)&#xD;
&#xD;
        3. Haemostatic function: Factor VII, fibrinogen, thrombin generation with and without&#xD;
           thrombomodulin, antithrombin (AT), tissue-type Plasminogen Activator (t-PA), Plasminogen&#xD;
           Activator Inhibitor-1(PAI-1), thrombin activatable fibrinolysis inhibitor (TAFI) and&#xD;
           activated TAFI (TAFIa), plasmin-antiplasmin complex, plasma fibrinolytic capacity;&#xD;
&#xD;
        4. Metabolic syndrome parameters: glycemia, triglycerides, HDL cholesterol, insulin e&#xD;
           insulin-resistance (HOMA-IR homeostasis model assessment-estimated insulin resistance),&#xD;
           adiponectin;&#xD;
&#xD;
        5. Apoptosis parameters: total cytokeratin-18 (M65 antigene), M30 and M65/M65ED, soluble&#xD;
           fas and soluble fas ligand.&#xD;
&#xD;
      A weekly food diary will be administered to each subject before and at the end of the&#xD;
      treatment, to highlight any possible change of dietary habits during the study.&#xD;
&#xD;
      In addition, for all subjects the NAFLD Fibrosis Score (NFS), a composite score of prognostic&#xD;
      value for the conversion of NAFDL into fibrotic hepatitis and for the disease severity, will&#xD;
      be calculated. This score includes age, body mass index, platelet count, albumin,&#xD;
      relationship between AST and ALT, and presence of diabetes. A sub-analysis will be done to&#xD;
      evaluate the efficacy of the treatment with the synergistic blend of ingredients in subjects&#xD;
      with high, as compared to those with low NFS.&#xD;
&#xD;
      Sample size calculation: Establishing Alpha = 0.05 and Β = 80%, the number of 150 people (75&#xD;
      per treatment arm) will evaluate differences between the two groups (T1 to T0) equal to 46%&#xD;
      of the standard deviation of the mean of the two liver function parameters selected (primary&#xD;
      end-points), in particular, differences over 11.5 for ALT (17% of the average), 7.1 for AST&#xD;
      (17% of the average) or 13.8 for γ-GT (19% of the average). This calculation also includes a&#xD;
      drop-out of 10% of the sample enrolled in the study.&#xD;
&#xD;
      Compliance to treatment will be monitored by counting the capsules returned in the box at the&#xD;
      end of treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 18, 2015</start_date>
  <completion_date type="Actual">September 15, 2016</completion_date>
  <primary_completion_date type="Actual">September 15, 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hematic Levels of Hepatic Enzymes AST</measure>
    <time_frame>before and at the end of treatment (three months)</time_frame>
    <description>hematic levels of hepatic enzyme: aspartate aminotransferase (AST)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Hematic Levels of Hepatic Enzymes ALT</measure>
    <time_frame>before and at the end of treatment (three months)</time_frame>
    <description>hematic levels of hepatic enzyme: alanine aminotransferase (ALT)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Hematic Levels of Hepatic Enzymes GGT</measure>
    <time_frame>before and at the end of treatment (three months)</time_frame>
    <description>hematic levels of hepatic enzyme: gamma-glutamyl transpeptidase (GGT)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma Levels of Hepatic Enzymes</measure>
    <time_frame>before and at the end of treatment (three months)</time_frame>
    <description>hematic levels of direct bilirubin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Levels of Circulating Inflammation Marker</measure>
    <time_frame>before and at the end of treatment (three months)</time_frame>
    <description>Levels of circulating Inflammation marker: C Reactive Protein (CRP)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measures of the Haemostatic Function</measure>
    <time_frame>before and at the end of treatment (three months)</time_frame>
    <description>Tissue-type Plasminogen Activator (t-PA) levels in plasma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measures of the Haemostatic Function</measure>
    <time_frame>before and at the end of treatment (three months)</time_frame>
    <description>Plasminogen Activator Inihibitor (PAI-1) levels in plasma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measures of the Haemostatic Function</measure>
    <time_frame>before and at the end of treatment (three months)</time_frame>
    <description>Thrombin activatable fibrinolysis inhibitor (TAFI) levels in plasma</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">126</enrollment>
  <condition>Non-alcoholic Fatty Liver Disease</condition>
  <arm_group>
    <arm_group_label>nutraceutical mixture</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Lifestyle counseling plus three month administration of nutraceutical mixture (2 soft gelatin capsules of 800 mg per day)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Lifestyle counseling plus three month administration of placebo formulation (2 soft gelatin capsules of 800 mg per day)</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>nutraceutical mixture</intervention_name>
    <description>Lifestyle counseling, administration of a nutraceutical mixture: fish oil 70% DHA (docosahexaenoic acid), phosphatidylcholine concentrated in sunflower oil, silymarin, choline bitartrate, curcumin, D-α-tocopherol; choline (82,5 mg, corresponding to 15% of the average intake of 550 mg per day in an adult man)</description>
    <arm_group_label>nutraceutical mixture</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Lifestyle counseling, administration of a placebo, containing only choline, at the same low concentration of the active mixture</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  subjects with non alcoholic fatty liver disease (NAFLD)&#xD;
&#xD;
          -  presenting ultrasonographic abnormalities of steatosic liver (hyperechogenic&#xD;
             parenchyma)&#xD;
&#xD;
          -  with plasma levels greater than normal (ranges of each recruiting center) for at least&#xD;
             one of the following parameters (aspartate aminotransferase AST, alanine&#xD;
             aminotransferase ALT, γ -glutamyltranspeptidase γ-GT).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  history of alcohol abuse&#xD;
&#xD;
          -  use of drugs associated with the development of hepatic steatosis&#xD;
&#xD;
          -  malnutrition&#xD;
&#xD;
          -  alcoholic chronic liver disease&#xD;
&#xD;
          -  chronic liver disease of different etiology (autoimmune disease, primary biliary&#xD;
             cirrhosis, primary sclerosing cholangitis, hereditary hemochromatosis, Wilson's&#xD;
             disease, deficits of alpha-1 antitrypsin, celiac disease)&#xD;
&#xD;
          -  severe renal, cardiac or respiratory insufficiency&#xD;
&#xD;
          -  malignant tumors&#xD;
&#xD;
          -  intolerance to any component of the active ingredients of the formulation&#xD;
&#xD;
          -  women who are pregnant or have planned the pregnancy within three months and women who&#xD;
             are breast-feeding.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Giovanni de Gaetano, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>IRCCS Neuromed</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>IRCCS Neuromed</name>
      <address>
        <city>Pozzilli</city>
        <state>Isernia</state>
        <zip>86077</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, Charlton M, Sanyal AJ; American Association for the Study of Liver Diseases; American College of Gastroenterology; American Gastroenterological Association. The diagnosis and management of non-alcoholic fatty liver disease: Practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Am J Gastroenterol. 2012 Jun;107(6):811-26. doi: 10.1038/ajg.2012.128. Erratum in: Am J Gastroenterol. 2012 Oct;107(10):1598.</citation>
    <PMID>22641309</PMID>
  </reference>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>February 17, 2015</study_first_submitted>
  <study_first_submitted_qc>February 23, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 24, 2015</study_first_posted>
  <results_first_submitted>September 8, 2020</results_first_submitted>
  <results_first_submitted_qc>January 26, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">February 15, 2021</results_first_posted>
  <last_update_submitted>February 23, 2021</last_update_submitted>
  <last_update_submitted_qc>February 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Neuromed IRCCS</investigator_affiliation>
    <investigator_full_name>Giovanni de Gaetano</investigator_full_name>
    <investigator_title>Head, Department Epidemiology and Prevention</investigator_title>
  </responsible_party>
  <keyword>NAFLD</keyword>
  <keyword>nutraceutical mixture</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Nutraceutical Mixture</title>
          <description>Lifestyle counseling plus three month administration of nutraceutical mixture (2 soft gelatin capsules of 800 mg per day)&#xD;
nutraceutical mixture: Lifestyle counseling, administration of a nutraceutical mixture: fish oil 70% DHA (docosahexaenoic acid), phosphatidylcholine concentrated in sunflower oil, silymarin, choline bitartrate, curcumin, D-α-tocopherol; choline (82,5 mg, corresponding to 15% of the average intake of 550 mg per day in an adult man)</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Lifestyle counseling plus three month administration of placebo formulation (2 soft gelatin capsules of 800 mg per day)&#xD;
placebo: Lifestyle counseling, administration of a placebo, containing only choline, at the same low concentration of the active mixture</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="62"/>
                <participants group_id="P2" count="64"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="55"/>
                <participants group_id="P2" count="58"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Nutraceutical Mixture</title>
          <description>Lifestyle counseling plus three month administration of nutraceutical mixture (2 soft gelatin capsules of 800 mg per day)&#xD;
nutraceutical mixture: Lifestyle counseling, administration of a nutraceutical mixture: fish oil 70% DHA (docosahexaenoic acid), phosphatidylcholine concentrated in sunflower oil, silymarin, choline bitartrate, curcumin, D-α-tocopherol; choline (82,5 mg, corresponding to 15% of the average intake of 550 mg per day in an adult man)</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Lifestyle counseling plus three month administration of placebo formulation (2 soft gelatin capsules of 800 mg per day)&#xD;
placebo: Lifestyle counseling, administration of a placebo, containing only choline, at the same low concentration of the active mixture</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="55"/>
            <count group_id="B2" value="58"/>
            <count group_id="B3" value="113"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <population>Subjects lost at follow-up: 7 in the active group and 6 in the control group.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="47"/>
                    <measurement group_id="B2" value="47"/>
                    <measurement group_id="B3" value="94"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <population>Subjects lost at follow-up:&#xD;
7 in the active group, for: bone fracture (1), relocation to another city (1), discontinued supplementation for dermatitis (1), unmotivated personal decision (4);&#xD;
6 in the control group, for: discontinued supplementation for faecal color abnormality (green faeces, 1), unmotivated personal decision (5)</population>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55.7" spread="12.2"/>
                    <measurement group_id="B2" value="53.4" spread="11.3"/>
                    <measurement group_id="B3" value="54.6" spread="11.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <population>Subjects lost at follow-up: 7 in the active group and 6 in the control group.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="39"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                    <measurement group_id="B2" value="39"/>
                    <measurement group_id="B3" value="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <population>Subjects lost at follow-up: 7 in the active group and 6 in the control group.</population>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Italy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55"/>
                    <measurement group_id="B2" value="58"/>
                    <measurement group_id="B3" value="113"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Hematic Levels of Hepatic Enzymes AST</title>
        <description>hematic levels of hepatic enzyme: aspartate aminotransferase (AST)</description>
        <time_frame>before and at the end of treatment (three months)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Nutraceutical Mixture</title>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
          </group>
        </group_list>
        <measure>
          <title>Hematic Levels of Hepatic Enzymes AST</title>
          <description>hematic levels of hepatic enzyme: aspartate aminotransferase (AST)</description>
          <units>IU/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>before treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.4" spread="22.5"/>
                    <measurement group_id="O2" value="37.5" spread="25.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>after 3 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.6" spread="15"/>
                    <measurement group_id="O2" value="31.2" spread="14.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Intention-to-treat-analysis. Differences between basal values in active and control groups and between T1 vsT0 changes in the two groups assessed by ANOVA and Fisher's exact test.</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Hematic Levels of Hepatic Enzymes ALT</title>
        <description>hematic levels of hepatic enzyme: alanine aminotransferase (ALT)</description>
        <time_frame>before and at the end of treatment (three months)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Nutraceutical Mixture</title>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
          </group>
        </group_list>
        <measure>
          <title>Hematic Levels of Hepatic Enzymes ALT</title>
          <description>hematic levels of hepatic enzyme: alanine aminotransferase (ALT)</description>
          <units>IU/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>before treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.5" spread="28.4"/>
                    <measurement group_id="O2" value="48.3" spread="43.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>after 3 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.8" spread="22.9"/>
                    <measurement group_id="O2" value="40.0" spread="21.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Hematic Levels of Hepatic Enzymes GGT</title>
        <description>hematic levels of hepatic enzyme: gamma-glutamyl transpeptidase (GGT)</description>
        <time_frame>before and at the end of treatment (three months)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Nutraceutical Mixture</title>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
          </group>
        </group_list>
        <measure>
          <title>Hematic Levels of Hepatic Enzymes GGT</title>
          <description>hematic levels of hepatic enzyme: gamma-glutamyl transpeptidase (GGT)</description>
          <units>IU/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>before treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="101.4" spread="101.0"/>
                    <measurement group_id="O2" value="98.5" spread="136.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>after 3 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87.2" spread="71.1"/>
                    <measurement group_id="O2" value="75.6" spread="64.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Levels of Hepatic Enzymes</title>
        <description>hematic levels of direct bilirubin</description>
        <time_frame>before and at the end of treatment (three months)</time_frame>
        <population>direct bilirubin</population>
        <group_list>
          <group group_id="O1">
            <title>Nutraceutical Mixture</title>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
          </group>
        </group_list>
        <measure>
          <title>Plasma Levels of Hepatic Enzymes</title>
          <description>hematic levels of direct bilirubin</description>
          <population>direct bilirubin</population>
          <units>microM/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>before treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.05" spread="1.2"/>
                    <measurement group_id="O2" value="2.74" spread="2.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 months after</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.22" spread="1.2"/>
                    <measurement group_id="O2" value="2.39" spread="1.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Intention-to-treat-analysis. Differences between basal values in active and control groups and between T1 vsT0 changes in the two groups assessed by ANOVA and Fisher's exact test.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Levels of Circulating Inflammation Marker</title>
        <description>Levels of circulating Inflammation marker: C Reactive Protein (CRP)</description>
        <time_frame>before and at the end of treatment (three months)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Nutraceutical Mixture</title>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
          </group>
        </group_list>
        <measure>
          <title>Levels of Circulating Inflammation Marker</title>
          <description>Levels of circulating Inflammation marker: C Reactive Protein (CRP)</description>
          <units>nmol/L</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>before treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.0" lower_limit="13.3" upper_limit="38.1"/>
                    <measurement group_id="O2" value="28.3" lower_limit="3.4" upper_limit="44.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 months after</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.1" lower_limit="12.9" upper_limit="30.5"/>
                    <measurement group_id="O2" value="24.0" lower_limit="13.3" upper_limit="41.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Measures of the Haemostatic Function</title>
        <description>Tissue-type Plasminogen Activator (t-PA) levels in plasma</description>
        <time_frame>before and at the end of treatment (three months)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Nutraceutical Mixture</title>
            <description>Lifestyle counseling plus three month administration of nutraceutical mixture (2 soft gelatin capsules of 800 mg per day)&#xD;
nutraceutical mixture: Lifestyle counseling, administration of a nutraceutical mixture: fish oil 70% DHA (docosahexaenoic acid), phosphatidylcholine concentrated in sunflower oil, silymarin, choline bitartrate, curcumin, D-α-tocopherol; choline (82,5 mg, corresponding to 15% of the average intake of 550 mg per day in an adult man)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Lifestyle counseling plus three month administration of placebo formulation (2 soft gelatin capsules of 800 mg per day)&#xD;
placebo: Lifestyle counseling, administration of a placebo, containing only choline, at the same low concentration of the active mixture</description>
          </group>
        </group_list>
        <measure>
          <title>Measures of the Haemostatic Function</title>
          <description>Tissue-type Plasminogen Activator (t-PA) levels in plasma</description>
          <units>ng/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>before treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.6" spread="4.8"/>
                    <measurement group_id="O2" value="10.1" spread="9.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>after 3 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.7" spread="4.9"/>
                    <measurement group_id="O2" value="9.9" spread="8.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Measures of the Haemostatic Function</title>
        <description>Plasminogen Activator Inihibitor (PAI-1) levels in plasma</description>
        <time_frame>before and at the end of treatment (three months)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Nutraceutical Mixture</title>
            <description>Lifestyle counseling plus three month administration of nutraceutical mixture (2 soft gelatin capsules of 800 mg per day)&#xD;
nutraceutical mixture: Lifestyle counseling, administration of a nutraceutical mixture: fish oil 70% DHA (docosahexaenoic acid), phosphatidylcholine concentrated in sunflower oil, silymarin, choline bitartrate, curcumin, D-α-tocopherol; choline (82,5 mg, corresponding to 15% of the average intake of 550 mg per day in an adult man)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Lifestyle counseling plus three month administration of placebo formulation (2 soft gelatin capsules of 800 mg per day)&#xD;
placebo: Lifestyle counseling, administration of a placebo, containing only choline, at the same low concentration of the active mixture</description>
          </group>
        </group_list>
        <measure>
          <title>Measures of the Haemostatic Function</title>
          <description>Plasminogen Activator Inihibitor (PAI-1) levels in plasma</description>
          <units>ng/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>before treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.7" spread="19.8"/>
                    <measurement group_id="O2" value="48.0" spread="18.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>after 3 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.3" spread="18.4"/>
                    <measurement group_id="O2" value="47.7" spread="21.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Measures of the Haemostatic Function</title>
        <description>Thrombin activatable fibrinolysis inhibitor (TAFI) levels in plasma</description>
        <time_frame>before and at the end of treatment (three months)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Nutraceutical Mixture</title>
            <description>Lifestyle counseling plus three month administration of nutraceutical mixture (2 soft gelatin capsules of 800 mg per day)&#xD;
nutraceutical mixture: Lifestyle counseling, administration of a nutraceutical mixture: fish oil 70% DHA (docosahexaenoic acid), phosphatidylcholine concentrated in sunflower oil, silymarin, choline bitartrate, curcumin, D-α-tocopherol; choline (82,5 mg, corresponding to 15% of the average intake of 550 mg per day in an adult man)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Lifestyle counseling plus three month administration of placebo formulation (2 soft gelatin capsules of 800 mg per day)&#xD;
placebo: Lifestyle counseling, administration of a placebo, containing only choline, at the same low concentration of the active mixture</description>
          </group>
        </group_list>
        <measure>
          <title>Measures of the Haemostatic Function</title>
          <description>Thrombin activatable fibrinolysis inhibitor (TAFI) levels in plasma</description>
          <units>% of reference plasma</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>before treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="105" spread="23"/>
                    <measurement group_id="O2" value="100" spread="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>after 3 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="104" spread="23"/>
                    <measurement group_id="O2" value="99" spread="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>3 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Nutraceutical Mixture</title>
          <description>Lifestyle counseling plus three month administration of nutraceutical mixture (2 soft gelatin capsules of 800 mg per day)&#xD;
nutraceutical mixture: Lifestyle counseling, administration of a nutraceutical mixture: fish oil 70% DHA (docosahexaenoic acid), phosphatidylcholine concentrated in sunflower oil, silymarin, choline bitartrate, curcumin, D-α-tocopherol; choline (82,5 mg, corresponding to 15% of the average intake of 550 mg per day in an adult man)</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Lifestyle counseling plus three month administration of placebo formulation (2 soft gelatin capsules of 800 mg per day)&#xD;
placebo: Lifestyle counseling, administration of a placebo, containing only choline, at the same low concentration of the active mixture</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Chiara Cerletti, operative responsible of the trial and corresponding author of the data public</name_or_title>
      <organization>IRCCS Neuromed</organization>
      <phone>0865915246</phone>
      <email>chiara.cerletti@moli-sani.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

